Cuiqin Wang, Xiaobing Wang, Pingxiu He, Xiaohua Tao, Weijun Liu
{"title":"Successful Treatment of Refractory Livedoid Vasculopathy with Upadacitinib: A Case Report.","authors":"Cuiqin Wang, Xiaobing Wang, Pingxiu He, Xiaohua Tao, Weijun Liu","doi":"10.2147/CCID.S556844","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>While tofacitinib, baricitinib, and abrocitinib demonstrate efficacy in livedoid vasculopathy (LV), this study evaluates upadacitinib-a distinct Janus kinase (JAK) inhibitor-in refractory LV.</p><p><strong>Patients and methods: </strong>A 54-year-old female with treatment-resistant LV received upadacitinib (15 mg/day). Treatment response was assessed via composite clinical scores pre- and post-therapy.</p><p><strong>Results: </strong>Significant improvement occurred within 24 days (score: 7→2), indicating remission. Pain intensity markedly decreased, and near-complete ulcer healing was observed by day 52. No adverse effects were observed, with the exception of orolabial herpes simplex.</p><p><strong>Conclusion: </strong>Upadacitinib represents a novel therapeutic alternative for LV. Larger cohorts are needed to validate these findings.</p>","PeriodicalId":10447,"journal":{"name":"Clinical, Cosmetic and Investigational Dermatology","volume":"18 ","pages":"2645-2650"},"PeriodicalIF":2.2000,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12533487/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical, Cosmetic and Investigational Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CCID.S556844","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: While tofacitinib, baricitinib, and abrocitinib demonstrate efficacy in livedoid vasculopathy (LV), this study evaluates upadacitinib-a distinct Janus kinase (JAK) inhibitor-in refractory LV.
Patients and methods: A 54-year-old female with treatment-resistant LV received upadacitinib (15 mg/day). Treatment response was assessed via composite clinical scores pre- and post-therapy.
Results: Significant improvement occurred within 24 days (score: 7→2), indicating remission. Pain intensity markedly decreased, and near-complete ulcer healing was observed by day 52. No adverse effects were observed, with the exception of orolabial herpes simplex.
Conclusion: Upadacitinib represents a novel therapeutic alternative for LV. Larger cohorts are needed to validate these findings.
期刊介绍：
Clinical, Cosmetic and Investigational Dermatology is an international, peer-reviewed, open access journal that focuses on the latest clinical and experimental research in all aspects of skin disease and cosmetic interventions. Normal and pathological processes in skin development and aging, their modification and treatment, as well as basic research into histology of dermal and dermal structures that provide clinical insights and potential treatment options are key topics for the journal.
Patient satisfaction, preference, quality of life, compliance, persistence and their role in developing new management options to optimize outcomes for target conditions constitute major areas of interest.
The journal is characterized by the rapid reporting of clinical studies, reviews and original research in skin research and skin care.
All areas of dermatology will be covered; contributions will be welcomed from all clinicians and basic science researchers globally.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
